Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Supranuclear Palsy, Progressive

ClinicalTrials.gov lists 169 trials for Supranuclear Palsy, Progressive or a narrower condition beneath it.

MeSH D013494 Nervous System Diseases C10 C11 C23 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 25 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 21 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 6 Phase 4 Phase 4 2 Not applicable Not applicable 42 Observational Observational 65 Phase 1 Phase 1 25 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 21 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 6 Phase 4 Phase 4 2 Not applicable Not applicable 42 Observational Observational 65

Trials per phase (log scale)

169 of the 169 trials are tagged with Supranuclear Palsy, Progressive itself; the rest are tagged with a narrower condition beneath it.

Get the Supranuclear Palsy, Progressive report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Supranuclear Palsy, Progressive trials start? (25)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 17

1995: 1 trials (Observational 1) 2000: 2 trials (Phase 3 1, Phase 2 1) 2003: 1 trials (Observational 1) 2004: 2 trials (Not applicable 1, Phase 2/3 1) 2006: 5 trials (Observational 2, Not applicable 1, Phase 2 2) 2007: 2 trials (Observational 2) 2008: 3 trials (Observational 1, Phase 2 1, Phase 1/2 1) 2009: 1 trials (Not applicable 1) 2010: 5 trials (Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 1/2 1, Phase 1 1) 2011: 3 trials (Observational 3) 2012: 6 trials (Observational 2, Not applicable 3, Phase 1/2 1) 2013: 5 trials (Observational 2, Not applicable 2, Phase 1 1) 2014: 6 trials (Observational 2, Not applicable 1, Phase 1 3) 2015: 9 trials (Observational 1, Not applicable 3, Phase 1 5) 2016: 13 trials (Observational 6, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1 3) 2017: 11 trials (Observational 5, Not applicable 4, Phase 3 1, Phase 2 1) 2018: 7 trials (Observational 1, Not applicable 2, Phase 2 1, Phase 1 3) 2019: 10 trials (Observational 5, Phase 4 2, Phase 2 1, Phase 1 2) 2020: 9 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 2) 2021: 17 trials (Observational 6, Not applicable 4, Phase 2 4, Phase 1/2 1, Phase 1 2) 2022: 11 trials (Observational 5, Not applicable 5, Phase 1 1) 2023: 9 trials (Observational 6, Phase 2/3 1, Phase 2 2) 2024: 9 trials (Observational 3, Not applicable 4, Phase 2 2) 2025: 9 trials (Observational 3, Not applicable 4, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 12
2025 9
2024 9
2023 9
2022 11
2021 17
2020 9
2019 10
2018 7
2017 11

Showing 10 of 25 earlier years.

Start your 14-day trial Email me all 25 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 15 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 88 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Supranuclear Palsy, Progressive trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 25
Phase 1/2 5
Phase 2 21
Phase 2/3 3
Phase 3 6
Phase 4 2
Not applicable 42
Observational 65

How many Supranuclear Palsy, Progressive trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 7
Recruiting 33
Enrolling by invitation 4
Active, not recruiting 11
Completed 82

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Supranuclear Palsy, Progressive trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AbbVie 3
Biogen 3
National Institute of Neurological Disorders and Stroke (NINDS) 3

Which drugs are being tested for Supranuclear Palsy, Progressive? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
BIIB092 3
CoQ10 3
ABBV-8E12 3
GV1001 2
UCB0107 2

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Observational Study 3
18F-Florbetapir 2
[18F]MNI-958 2
AADvac1 2
[18F]-PI2620 2

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Supranuclear Palsy, Progressive trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Fall 73 3
Pneumonia aspiration 33 2
FALL 22 2
Pneumonia 22 2
Progressive supranuclear palsy 18 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Supranuclear Palsy, Progressive? (101)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Deep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025 Yes
Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy. Annals of neurology 2024 Yes
CSF Proteomics in Patients With Progressive Supranuclear Palsy. Neurology 2024 Yes
Remote at-home wearable-based gait assessments in Progressive Supranuclear Palsy compared to Parkinson's Disease. BMC neurology 2023 Yes
Differences in Motor Features of <i>C9orf72</i>, <i>MAPT</i>, or <i>GRN</i> Variant Carriers With Familial Frontotemporal Lobar Degeneration. Neurology 2022 Yes

Showing 5 of 101 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (30)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Progressive supranuclear palsy Point prevalence 1-9 / 100 000 United Kingdom GB Unspecified
Progressive supranuclear palsy Point prevalence 1-9 / 100 000 United Kingdom GB Exact
Progressive supranuclear palsy Point prevalence 1-9 / 100 000 United Kingdom GB Exact
Progressive supranuclear palsy Annual incidence 1-9 / 1 000 000 United States US Exact
Progressive supranuclear palsy Annual incidence 1-9 / 1 000 000 United States US Unspecified

Showing 5 of 30 prevalence observations.

Start your 14-day trial Email me all 30 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Progressive supranuclear palsy 683 Exact Orphanet Rare Disease Ontology (ORDO)
Progressive supranuclear palsy 683 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages